risankizumab,ustekinumab,vedolizumab
abbvie,janssen,takeda
[' vedo', 'risan', 'ustekinumab']
 the getaid study will be published in the coming days in . in about 100 patients with anti-tnf, vedo and ustekinumab failure, risankizumab induction : clinical response &gt; 70% of patients and remission in 50% 
MD, PhD, Professor of gastroenterology, EPIMAD registry, focus on IBD, Amiens-Picardie university hospital, France